Elan Sets Up For Sale With Neotope Biosciences Spinout
Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.
Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.